PharmaJet announced today that its partner, Scancell, chose its needle-free injection platform to administer its COVID-19 vaccine candidates.
Scancell selected Golden, Colorado-based PharmaJet’s devices to administer two SARS-CoV-2 DNA-based vaccine candidates, SCOV1 and SCOV2. The vaccines will be exclusively administered using the PharmaJet Tropis and PharmaJet Stratis needle-free injection systems.
According to a news release, Scancell’s COVIDITY-001 study, which includes the use of the two PharmaJet systems, received approval from the South African regulatory authority following preclinical studies that demonstrated potent immune responses against both S and N antigens with PharmaJet’s delivery of the vaccines.
“Our preclinical studies have shown that delivery of SCOV1 and SCOV2 with the PharmaJet needle-free injection systems generates excellent T cell and antibody responses,” Scancell CEO Lindy Durrant said in the release. “In addition, they are easy-to-use and ideal for people who are needle-phobic, an important cause of vaccine hesitancy. We look forward to progressing our COVIDITY-001 study in South Africa and updating the market in due course.”
PharmaJet currently has enrollment underway in Australia for a Phase 1 clinical trial for its needle-free injection with Covigen, a DNA-based vaccine candidate developed by French-Thai pharmaceutical company BioNet-Asia in collaboration with Melbourne, Australia-based Technovalia.
“We are pleased to be collaborating with Scancell as they start their clinical trials with this innovative vaccine approach,” PharmaJet president & CEO Chris Capello said. “Our needle-free systems have shown improved immune response for multiple DNA and RNA vaccines and are used globally to deliver vaccines for diseases such as influenza, COVID-19, measles and polio.”
